Abbott Labs SEC Filings

Veritex Holdings, Inc. (VBTX) has filed a Form S-8 to register up to 1,650,000 additional shares of its $0.01 par value common stock for issuance under employee equity plans. The filing covers (i) 750,000 shares tied to outstanding awards granted under the shareholder-approved 2022 Amended and Restated Omnibus Incentive Plan and (ii) 900,000 newly authorized shares available under the recently approved 2025 Amended and Restated Omnibus Incentive Plan.

The 2025 Plan, adopted by the board on 25 Apr 2025 and ratified by shareholders on 27 May 2025, amends and restates the 2022 Plan and further expands the company’s long-term incentive capacity. Earlier plans included the 2014 Plan (1 million shares) and the 2019 Plan (1.5 million shares).

No proceeds flow directly to the company at the time of registration; actual cash inflow, if any, will occur upon option exercise or settlement of awards for cash. The filing reiterates Texas law–based indemnification provisions for directors and officers and lists customary undertakings required by the Securities Act.

For investors, the key consideration is the potential dilution from issuing up to 1.65 million additional shares, offset by the strategic objective of aligning management and employee incentives with shareholder interests. The impact magnitude will depend on Veritex’s total shares outstanding and the pace at which awards vest or are exercised.

Gap Inc. (GPS) – Form 4 insider filing

Director and 10 % owner Robert J. Fisher reported two equity-based awards dated 06/30/2025:

• Dividend Equivalent Rights: 1,381.6228 rights acquired at $0; each equals one common share; immediately vested with delivery deferred up to three years or upon Board departure.
• Stock Units: 8,482 units granted at $0; immediately vested; delivery subject to the same deferral schedule.

No common shares were bought or sold and no cash changed hands. After the grant, Fisher directly holds 55,264 stock units plus the newly accrued 1,381.6228 dividend rights. The transaction reflects routine director compensation, does not affect Gap’s share count, and carries minimal valuation or control implications for public shareholders.

Meta Platforms, Inc. (NASDAQ: META) – Form 144 filing discloses that Mark Zuckerberg intends to sell an additional 13,793 Class A common shares on or about 01 July 2025. The broker named for the transaction is Charles Schwab & Co., Inc. and the filing lists an aggregate market value of $9.98 million for the proposed sale. The shares were originally acquired via an option exercise on 17 May 2012 and will be sold on the NASDAQ exchange.

The form also details 13 prior sales executed by Mr. Zuckerberg between 06 June 2025 and 30 June 2025. During this period he disposed of approximately 124,846 shares for total gross proceeds of ≈ $89.0 million. Individual transactions ranged from 500 to 13,793 shares, with proceeds per trade between roughly $0.35 million and $10.21 million.

Key takeaways:

• Continued insider selling pattern by Meta’s Chief Executive Officer within a single quarter.
• Upcoming sale represents a small fraction (≈0.006%) of Meta’s reported 2.17 billion shares outstanding, but may signal ongoing liquidity diversification.
• Sale is being filed under Rule 144, indicating shares are not subject to a lock-up and that the insider affirms no undisclosed material information.

Form 4 filing overview: Abbott Laboratories (ABT) Executive Vice President Louis H. Morrone reported one transaction dated 30 June 2025.

• Transaction code: F (as reported in the form).
• Shares affected: 269 common shares without par value.
• Transaction price: $134.38 per share.
• Post-transaction direct holdings: 66,609 common shares.
• Indirect holdings: 12 common shares held in the Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) as of 30 June 2025.

There were no derivative security transactions reported and no indication of additional purchases, option exercises, or sales beyond the single Code F entry. Morrone remains an insider with substantial equity exposure to Abbott Laboratories after the reported withholding.

Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering Autocallable Contingent Coupon Equity-Linked Securities tied to Marvell Technology, Inc. (MRVL). Each unlisted note has a $1,000 denomination, will be issued on 2 Jul 2025 and will mature on 1 Jul 2027 unless redeemed earlier.

Yield mechanics: On each quarterly valuation date, investors earn a 3.75 % coupon (15 % p.a.) if MRVL’s closing price is at or above the Coupon Barrier of $38.194 (49.5 % of the initial $77.16). Missed coupons may “catch-up” if the barrier is later breached to the upside.

Autocall feature: Beginning 29 Dec 2025 and on five subsequent valuation dates, the notes are automatically called if MRVL closes at or above the initial price. Holders then receive $1,000 + the current coupon + any previously unpaid coupons, truncating further upside.

Downside at maturity: If not called and the Final Underlying Value is < $38.194, principal is converted into 12.96008 MRVL shares (or cash equivalent). A zero share price would wipe out the entire investment; there is no principal protection.

Pricing & fees: Issue price is $1,000; estimated value is $969 (≈3.1 % discount). Underwriting fee up to $18.50 (1.85 %), of which $17.50 is a selling concession and up to $1.00 a structuring fee. Total offering size is $2.863 million.

Risk highlights:

• Exposure to MRVL price on only eight observation dates increases path-dependence and volatility impact.
• Liquidity risk: notes will not be exchange-listed; secondary market is at Citigroup’s discretion.
• Credit risk of both the issuer and guarantor.
• Estimated value below issue price reflects fees, hedging costs and Citi’s internal funding rate.
• U.S. tax treatment uncertain; payments likely treated as ordinary income.

The product is designed for income-oriented investors who can tolerate equity downside, limited upside, early-call uncertainty and issuer credit risk in exchange for a potential 15 % annual coupon.

Form 4 filed 07/01/2025: Atlassian Corporation (TEAM) Co-Founder, CEO, Director and 10% owner Michael Cannon-Brookes converted 490,560 Class B shares into Class A shares (Transaction Code C). The Class B shares were held by CBC Co Pty Limited as trustee for the Cannon-Brookes Head Trust. The conversion was executed in connection with sales to be effected under a Rule 10b5-1 trading plan adopted on 02/20/2025.

Following the transaction, Cannon-Brookes’ reported holdings are:

• Class A common stock: 490,560 shares (indirect)
• Class B common stock (convertible one-for-one with no expiration): 48,024,933 shares (indirect)

No price was paid for the conversion (exercise price $0.00). The filing signals preparation for future open-market sales while complying with Section 16 reporting obligations and the updated Rule 10b5-1 affirmative-defense conditions.